Hot flushes and night sweats (HFNS) affect 65-85% of women after breast cancer treatment; they are distressing, causing sleep problems and decreased quality of life. Hormone replacement therapy is often either undesirable ...
Feb 14, 2012
0
0
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Jan 16, 2012
0
0
Giving overweight or obese patients a gut hormone that suppresses appetite leads to clinically beneficial weight loss as well as reduced blood pressure and cholesterol levels, finds a study published in the British Medical ...
Jan 10, 2012
1
0
(Medical Xpress) -- Bowel screening reduces the number of deaths from bowel cancer in Scotland by more than 25 per cent, according to research* presented at the National Cancer Research Institute (NCRI) Cancer Conference ...
Nov 9, 2011
0
0
The third paper in The Lancet Series on Global Mental Health examines mental health and psychosocial support (MHPSS) in humanitarian settings, and points out that most research and evidence is focused on interventions that ...
Oct 16, 2011
0
0
A study carried out by the Primary Care Research Group at the Peninsula College of Medicine and Dentistry, supported by the National Institute for Health Research (NIHR) and NIHR PenCLAHRC, has analysed the results of an ...
Oct 12, 2011
1
0
An updated study published in this week's PLoS Medicine gives some new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that among these commonly used drugs, naproxen ...
Sep 27, 2011
0
0
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) – an antibody-guided drug – for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast ...
Sep 25, 2011
0
0
Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients ...
Sep 23, 2011
0
0
The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of ...
Aug 30, 2011
0
0
